Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rated “Moderate Buy” by Sell-Side Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.83.

Several research firms recently commented on SRTS. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Finally, Lake Street Capital decreased their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $2.86 on Friday. The firm has a market capitalization of $47.08 million, a price-to-earnings ratio of -3.04 and a beta of 1.18. Sensus Healthcare has a 1 year low of $2.66 and a 1 year high of $5.49. The business has a fifty day moving average of $3.01 and a 200 day moving average of $3.50.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Insider Buying and Selling

In related news, Director Eric Sachetta bought 37,537 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was acquired at an average cost of $3.44 per share, with a total value of $129,127.28. Following the transaction, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This trade represents a 16.32% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 120,171 shares of company stock worth $405,230 over the last 90 days. 10.20% of the stock is currently owned by company insiders.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently modified their holdings of SRTS. EP Wealth Advisors LLC purchased a new position in Sensus Healthcare in the second quarter valued at $49,000. BlackRock Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter valued at about $252,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Sensus Healthcare during the 2nd quarter worth approximately $303,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.

Founded in 2010, Sensus Healthcare is headquartered in Boca Raton, Florida.